國立虎尾科技大學 |

Drug Treatment of Sleep Disorders

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Drug Treatment of Sleep Disorders/ edited by Antonio Guglietta.
其他作者:	Guglietta, Antonio.
面頁冊數:	VIII, 297 p. 23 illus., 14 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-3-319-11514-6
ISBN:	9783319115146

Drug Treatment of Sleep Disorders
Drug Treatment of Sleep Disorders[electronic resource] /edited by Antonio Guglietta. - 1st ed. 2015. - VIII, 297 p. 23 illus., 14 illus. in color.online resource. - Milestones in Drug Therapy,2296-6056. - Milestones in Drug Therapy,.

An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.

Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.

ISBN: 9783319115146

Standard No.: 10.1007/978-3-319-11514-6doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

Drug Treatment of Sleep Disorders
LDR:03015nam a22004095i 4500 001 967418
003 DE-He213
005 20200629142945.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319115146 $9 978-3-319-11514-6
024 7 $a 10.1007/978-3-319-11514-6 $2 doi
035 $a 978-3-319-11514-6
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Drug Treatment of Sleep Disorders $h [electronic resource] / $c edited by Antonio Guglietta.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a VIII, 297 p. 23 illus., 14 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Milestones in Drug Therapy, $x 2296-6056
505 0 $a An overview of sleep physiology and sleep regulation -- Neuronal networks regulating sleep and arousal: effect of drugs -- Classification of sleep disorders -- Development of new therapeutical agents for treatment of insomnia and other sleep disorders -- Low dose doxepin for insomnia -- Lorediplon: a new GABAa modulator drug for treatment of insomnia -- Zolpidem sublingual formulations -- Eszopiclone: review and clinical applications in chronic and co-morbid insomnia -- Orexin/hypocretin antagonists in insomnia: from bench to clinic -- Modafinil and armodafinil -- Sodium oxybate (Xyrem®): a new and effective treatment for narcolepsy with cataplexy -- Cell therapy to treat narcolepsy -- Tasimelteon -- The past, present and future of drug development and treatment in sleep disorders.
520 $a Following reviews on sleep physiology, regulation, pharmacology, and the neuronal networks regulating sleep and awakening, as well as a classification of sleep disorders, this book presents a number of major breakthroughs in the treatment of those disorders. These include recently approved drugs for treating insomnia, such as Doxepin; variations on previously approved molecules, e.g. Zolpidem sublingual preparation; or new chemical entities in advanced stages of clinical development, e.g. Orexin antagonists. Further topics discussed include drugs acting on the GABA receptor, such as Lorediplon and Eszopiclone; the treatment of excessive daytime drowsiness with cell therapy and drugs such as Modafinil, Armodafinil and Sodium oxybate; and the use of Tasimelteon in the treatment of circadian sleep disorders.
650 0 $a Pharmacology. $3 583819
650 0 $a Neurosciences. $3 593561
650 0 $a Pharmacotherapy. $3 973587
650 0 $a Psychopharmacology. $3 644799
650 1 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Guglietta, Antonio. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1063768
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319115153
776 0 8 $i Printed edition: $z 9783319115139
776 0 8 $i Printed edition: $z 9783319379203
830 0 $a Milestones in Drug Therapy, $x 2296-6056 $3 1263085
856 4 0 $u https://doi.org/10.1007/978-3-319-11514-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)